Hypotension News and Research

RSS

Nonmotor symptoms common in early-stage PD

Nonmotor symptoms occur in nearly all individuals with Parkinson’s disease, Italian study results suggest.

17 Oct 2012

Dopaminergic treatment has ‘minor impact’ on autonomic symptoms in Parkinson’s

Norwegian researchers say that dopaminergic treatment should be considered for patients with early Parkinson’s disease after finding that dopaminergic medication only has a minor impact on autonomic symptoms after 1 year.

17 Oct 2012

Neuroprotectant success in aneurysm coiling

Treatment with the novel neuroprotective agent NA-1 reduces the number of ischemic infarcts sustained by patients undergoing coiling of cerebral aneurysms, show the ENACT results.

12 Oct 2012

Neuroprotectant success in aneurysm coiling

Treatment with the novel neuroprotective agent NA-1 reduces the number of ischemic infarcts sustained by patients undergoing coiling of cerebral aneurysms, show the ENACT results.

9 Oct 2012

Adjunctive drugs hasten sedation in the emergency department

Adding intravenous droperidol or olanzapine to midazolam shortens the time to adequate sedation in acutely agitated patients in the emergency department, show findings from a randomized controlled trial.

2 Oct 2012

Orthopedists should suspect necrotizing fasciitis in patients with out of proportion pain

Dr. Russell Russo, an Orthopedic Surgeon at LSU Health Sciences Center New Orleans, and other researchers stress that orthopedists should have a high index of suspicion for necrotizing fasciitis, or flesh-eating bacterial infection, in every patient with pain or other symptoms that are out of proportion to the initial diagnosis. Their recommendations are published in the September 2012 issue of Orthopedics Today.

17 Sep 2012

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

AMAG Pharmaceuticals, Inc. today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

6 Sep 2012

Renal denervation regenerates blood vessels and could reduce cardiovascular events

Renal denervation improves blood pressure and arterial stiffness in patients with therapy resistant hypertension, according to research presented at ESC Congress 2012 by Mr Klaas Franzen from the University Hospital of Schleswig-Holstein.

28 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Healthcare announces important changes to the U.S. product label for Optison

GE Healthcare today announced important changes to the U.S. product label for Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a contrast agent that may improve the visualization of the left ventricular border - an area of the heart that is critical to see in order to diagnose certain heart diseases such as hypertrophic cardiomyopathy.

22 Aug 2012

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Pfizer Inc. announced that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population.

12 Aug 2012

Pendrin a possible new target for diuretic therapy

In patients with fluid overload, inhibition of the chloride-absorbing transporter pendrin and the NaCl co-transporter may provide an effective diuretic regimen without triggering hypokalemia, research suggests.

6 Aug 2012

Further evidence for dermatologic benefits of propanolol

Results from a Greek study give further support to the use of propanolol as a first-line treatment for problematic infantile hemangiomas.

26 Jul 2012

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

AMAG Pharmaceuticals, Inc. today reported preliminary results from the second phase III study from its global registrational program for Feraheme (ferumoxytol) in patients with iron deficiency anemia (IDA) regardless of the underlying cause.

19 Jul 2012

UCB’s Neupro now available in U.S. pharmacies

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome.

16 Jul 2012

Hypotension News and Research

Nonmotor symptoms common in early-stage PD

Dopaminergic treatment has ‘minor impact’ on autonomic symptoms in Parkinson’s

Neuroprotectant success in aneurysm coiling

Neuroprotectant success in aneurysm coiling

Adjunctive drugs hasten sedation in the emergency department

Orthopedists should suspect necrotizing fasciitis in patients with out of proportion pain

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

Renal denervation regenerates blood vessels and could reduce cardiovascular events

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

Healthcare announces important changes to the U.S. product label for Optison

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Pendrin a possible new target for diuretic therapy

Further evidence for dermatologic benefits of propanolol

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

UCB’s Neupro now available in U.S. pharmacies

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

Five abstracts evaluating Abbott's LCIG presented at Parkinson's disease congress

Pfizer receives FDA Complete Response Letter for tafamidis meglumine NDA

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News